Adherence to Inhaled Medication Guidelines in Patients with COPD: Evaluating the GOLD 2023 Strategy in a Real-World Secondary Care Setting
A substantial proportion of patients with COPD are not treated in accordance with GOLD recommendations. While there may be valid reasons for deviating from the recommendations, these findings should prompt physicians to consider whether their patients' current treatment is optimal. Clear criteria exist for initiating ICS treatment. However, there is no data-driven evidence or consensus on how to manage ICS treatment once a patient has stabilised. Identifying and discussing the barriers for implementation of the GOLD strategy is essential.
Authors
- Joachim G.J.V. Aerts (ORCID: https://orcid.org/0000-0001-6662-2951)
- Huib A.M. Kerstjens (ORCID: https://orcid.org/0000-0001-7705-7927)
- Erik Bischoff (ORCID: https://orcid.org/0000-0002-3323-8475)
- Liz Cuperus (ORCID: https://orcid.org/0009-0009-6656-1015)
- J.C.C.M. in ’t Veen (ORCID: https://orcid.org/0000-0001-6828-2612)
- Job A.M. van der Palen (ORCID: https://orcid.org/0000-0003-1071-6769)
- Job F. M. van Boven (ORCID: https://orcid.org/0000-0003-2368-2262)
- Gwo-Ping Jong
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Medisch Spectrum Twente (NL)
- Erasmus MC (NL)
- Sint Franciscus Gasthuis (NL)
- Franciscus Vlietland (NL)
- University of Twente (NL)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/copd.s543458
- Citations
- 3
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Chiesi Farmaceutici